Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9368222 | 0.95 | LMNA (0.36) | LMNASMN1; SMN2ALOX12ADRA1AALDH1A1 | |
| SCHEMBL9368232 | 0.95 | LMNA (0.36) | LMNASMN1; SMN2ALOX12ADRA1AALDH1A1 | |
| SCHEMBL9372482 | 0.93 | LMNA (0.35) | LMNASMN1; SMN2ALOX12ADRA1AALDH1A1 | |
| SCHEMBL9372470 | 0.93 | LMNA (0.35) | LMNASMN1; SMN2ALOX12ADRA1AALDH1A1 | |
| SCHEMBL8476369 | 0.91 | LMNA (0.38) | LMNASMN1; SMN2ALOX12ADRA1AALDH1A1 | |
| SCHEMBL8476367 | 0.91 | LMNA (0.38) | LMNASMN1; SMN2ALOX12ADRA1AALDH1A1 | |
| SCHEMBL24922883 | 0.89 | LMNA (0.34) | LMNASMN1; SMN2ALOX12ADRA1AALDH1A1 | |
| SCHEMBL13366957 | 0.82 | TK1 (0.43) | LMNASMN1; SMN2ALOX12ADRA1AALDH1A1 | |
| SCHEMBL15740170 | 0.81 | LMNA (0.43) | LMNASMN1; SMN2ALDH1A1ALBMAPK1 | |
| SCHEMBL2619409 | 0.80 | LMNA (0.41) | LMNASMN1; SMN2ALOX12ADRA1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835625-B2 | Propargyl substituted nucleoside compounds and methods | APPLIED BIOSYSTEMS, LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120309953-A1 | Propargyl Substituted Nucleoside Compounds and Methods | Life Technologies Corporation (US) | 2012-12-06 | — | — | US | disclosed |
| US-7998706-B2 | Pyrimidine nucleobases | APPLIED BIOSYSTEMS, LLC (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | Life Technologies Corporation (US) | 2010-05-06 | — | — | US | disclosed |
| US-20050214843-A1 | Pyrimidine nucleobases | APPLERA CORPORATION (US) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113759-A1 | PROPARGYL SUBSTITUTED NUCLEOSIDE COMPOUNDS AND METHODS | PNP, NT5C3B, NUDT1 | LMNA 323/4885SMN1; SMN2 1906/4885ALOX12 3311/4885 |
| US-20120309953-A1 | Propargyl Substituted Nucleoside Compounds and Methods | PNP, NUDT1, DUT | LMNA 314/4885SMN1; SMN2 1528/4885ALOX12 3180/4885 |
| US-20050214843-A1 | Pyrimidine nucleobases | DPYD, PNP, UMPS | LMNA 1016/4885SMN1; SMN2 2111/4885ALOX12 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.